Lecture 2 Flashcards

1
Q

How can you define selective toxicity at a biochemical level?

A
  • Drug target unique to the parasite, e.g. dhps in plasmodium
  • Drug target with different structure and specificity in parasite and host, e.g. benzimidazoles for helminth beta-tubulin
  • Drug target activity in bost host and pathogen but effect on host not significant becuase of alternative pathways or high mammalian ezyme turnover, e.g. pyruvate kinase
  • Acitve drug is formed by metabolism only in parasite but not in host, e.g. 5-nitroimidazoles; in anaerobic pathogens d
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How can you define selective toxicity at a cellular level?

A
  • Drug only penetrates the parasite, due to different membrane composition
  • ## Drug uptake and localisation affected if parasite intracellular
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How can you define selective toxicity at the level of the host?

A

-Pharmacokinetics; how the drug affects the body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What must be considered for pharmacokinetics?

A
  • Route of administration
  • Adsorption
  • Distribution
  • metabolism
  • Excretion
  • Interaction with immune system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the key characteristics of an Antiparasitic drug target?

A
  • Essential for parasite growth or survival in the host
  • Selective inhibition possible with small molecules
  • Amenable to study at the molecular level
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What drugs target DHPS?

A

Sulphonamide drugs, e.g. sulphadoxine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What role does DHPS play in plasmodium?

A

Important in folate synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How was DHPS validated as a drug target?

A

Created Plasmodium falciparum mutants with resistance to sulphadoxine due to point mutants. Transgenic P. falciparum with mutant DHPS alleles - correlated with different levels of sulphadoxine resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which unique enzyme is a possible target to treat the Kinetoplastids?

A

Trypanothione reductase; removal of toxic oxygen radicals. 40% amino acid identity same as human variant but different enough to be targeted. Still no viable inhibitors have been found.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Give two example enzymes that are found in both host and parasite that could be targeted for treatment

A

1) DHFR-TS

2) NMT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What drug inhibits DHFR-TS? Why is it used on hosts?

A

Methotrexate

Treat arthritis, immunosuppressant and for cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How effective has methotrexate been in treatment of Leishmania?

A

In vivo activity disappointing - due to alternative folate synthetic pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Give an example of a piggy-back taregt

A

N-myristoyltransferase (NMT) inhibitors
Originally being developed for the treatment of pathogenic fungi but meant that all tools in place to study for treating parasite.
NMT is an enzyme that catalyses co-translational N-terminal addition of myrisitic acid to cellular proteins; aids sub-cellular targetting. NMT expression is essential for parasite viability in trypanosomatids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Outline the mode of action of metabolomics

A

1) Metabolites are grown in the presence and absence of drug
2) Metabolism is quenched, usually by rapid cooling in a dry ice ethanol bath for paraites
3) Medium is removed and metabolites extracted
4) Metabolites chromatographically separated
5) Metabolites detected using UV, mass spec or NMR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which drugs has metabolomics been shown to be effective in treating T. brucei?

A

Eflornithine, an ornithine decarboxylase (ODC) inhibitor
Nifurtimox, thought to be involved in DNA an RNA degradation
5-fluoroorotic acid and 5-fluorouracil, thought to degrade RNA
5-fluoro-2′deoxyuridine and 5-fluoro-2′deoxycytidine, inhibits the bifuntional dihydrofolate reductase-thymidylate synthase enzyme, leading to a large increase in dUMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What has metabolomics shown about treating Leishmania with SbIII (an antimonal)?

A

Causes an accumulation of disulfide forms of glutathione and trypanothione, diminishing the redox capacity of the parasites

17
Q

What effect has metabolomics shown miltefosine treatment to have on Leishmania?

A

Increase in alkaline fragments, indicating affects on lipid metabolism, and increases in nucelotides and sugars

18
Q

What is a large concern over the current drugs for Leishmania?

A

The development of multidrug resistant strains; strains immune to SbIII are usually given miltefosine, however some are beginning to show defects in their miltefosine uptake

19
Q

What effect has metabolomics shown Atovaquone treatment to have on Plasmodium falciparum?

A

Inhibit enzymes of the bc1 complex, causing membrane depolarization, proton pumping was disrupted and dihydroorotate dehydrogenase activity is also diminished, leading to a depletion in orotate levels, affecting pyrimidine synthesis

20
Q

What are the three sub-species of T. brucei?

A

T. brucei brucei (non-human infective)
T. brucei gambiense (chronic disease)
T. brucei rhodesiense (acute disease)

21
Q

What drugs exist to treat each stage of African trypanosomiasis?

A

Stage 1; pentamidine and suramin

Stage 2; Melarsoprol, eflotnithine and nifurtimox

22
Q

What are the issues with current drugs for African trypanosomiasis?

A

Toxic, resistance a problem, not adapted to field conditions and expensive

23
Q

How are antimonals metabolised to their active form?

A

Pentavalent antimonal given and metabolised in trivalent antimonal for acitivity

24
Q

How does amphotericin B target phagocytic cells?

A

Given in a liposomal formation

25
Q

Which disease was miltefosine piggybacked from?

Why is it no longer used for that disease?

A

Cancer

Caused birth defects, but still used for Leishmaniasis in India

26
Q

What is now commonly used for treating parasite infections?

A

Combinations of drugs

27
Q

What stage of parasite life cyle is targeted in Malaria treatments?

A

Blood stream stage; before entering the liver

28
Q

Why is drig resistance more likely to be a problem in Plasmodium falciparum than Leishmania major?

A

PF has no animal resevoir so entire popoulation could be exposed to drug in human host and resistance can be passed onto another human. Parasite burden high; 10^11. Haploid genome so point mutations have immediate effect. Whereas, LM has a major animal reservoir so exposure to drug is limited and resistant pathogen unlikely to be passed on to another human host. Parasite burden lower 10^5-7. Diploid genome so point mutations may have no effect is recessive.
Applies to all parasites not just these two.

29
Q

What can cause treatment failure?

A
  • Genetic differences in host
  • Mutation in parasite
  • Secondary infection with is changes metabolism of the drug
30
Q

What has been shown in a mouse model of visceral leishmaniasis about environmental drug resistance?

A

Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs

31
Q

How are antigens presented?

A

Uptake by endocytosis, macropintocytosis, or phagocytosis. In lysosome the target is cut up and given to MHC class II molecules, and trafficked to membrane. MHC class I deals with proteins made by host machinery, and trafficked to membrane.

32
Q

What type of epitope would be best for vaccines?

A

Promiscuous epitope - can bind to numerous histocompatibility alleles

33
Q

Why is it important to measure protein abundance when choosing antigens for vaccines?

A

If a protein is not very abundant but used in a vaccine may create excellent immune response against an antigen that is never going to presented on an MHC molecule

34
Q

How has the most advanced DNA vaccine be investigated?

A

Rationale screening using human T cells
Seeing what cells of patients have been infected are expressing; i.e. what part of the parasite is presented by the MHC in actual patients and hence what could make a good antigen for vaccine

35
Q

What vaccine for leishmaniasis is being developed in York?

A
ChAd63-KH
Viral vector carrying antigens which are expressed by MHC class I, as Leishmania interferes with MHC class II. Passed phase 1 clinical trials. Now going to clinical trial in Sudan